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Background:  Mechanical circulatory support (MCS) is frequently used to bridge patients with end-stage heart failure to heart 
transplantation (HTx). Previous studies have suggested a worse long-term outcome in cardiac transplant recipients who have been 
supported with MCS prior to HTx, in part related to an increased rate of antibody-mediated rejection (AMR). The aim of this study was 
to evaluate the impact of MCS on subsequent rejection post-HTx by using cellular (CR) and AMR rejection scores and correlating with 
subsequent allograft outcomes.
methods:  We retrospectively analyzed 160 patients who underwent HTx without (n=95) or with (n=65) previous MCS at Mayo Clinic, 
Rochester, USA between January 1, 2008 and May 31, 2014. The median follow up was 30 (38) months. Continuous flow left ventricular 
assist devices (LVADs), were implanted in 56 (86%) patients; pulsatile flow LVADs were implanted in 4 (6%), while 5 (8%) patients received 
extracorporeal devices alone or in combination with different type of LVAD. The cumulative effect of rejection was calculated by using CR 
and AMR scores, based on the total number of rejections divided by valid biopsy samples and the 2004 and 2011 International Society for 
Heart and Lung Transplantation R grading system. Consequently allograft outcomes (overall survival and vasculopathy) for period of 12, 24 
and 36 months were also evaluated. Vasculopathy was assessed by the both routine coronary angiogram and intravascular ultrasound.
results: Patients who underwent MCS implantation before HTx demonstrated a significant increase in the number of CR episodes, as 
compared to the non-bridged patients, for 1 and 2 years of follow-up (p=0.021 and p=0.019), respectively. There were no differences in 
AMR, between the groups during all periods of follow - up (p>0.05). Despite these findings, there were no differences in allograft outcomes, 
such as vasculopathy and overall survival, between these two groups, at 1, 2 and 3 years post - transplant.
conclusion:  Implantation of a MCS before HTx impacts CR during the post-transplant period. Despite these findings, MCS does not 
translate to differences in allograft outcomes, such as vasculopathy and overall survival.
